clinical dataNovartis’ $12B Avidity bet suffers Phase 3 blowNovartis has suffered another pipeline setback after del-desiran, an antibody-oligonucleotide conjugate acquired with Avidity Biosciences, failed to significantly improve hand function over placebo in … more ➔
financeGermany’s NRW state bets €200M on AI-powered cancer researchNorth Rhine-Westphalia (NRW), a state located in the North-West of Germany, is investing €200 million to connect university hospitals in Aachen, Bochum, Bonn, Düsseldorf, Essen, Cologne and Münster, … more ➔
startupsVaxdyn raises €11M Series A to test AMR vaccineSpanish biotech Vaxdyn has raised an €11 million Series A to take K-VAX, its vaccine against Klebsiella pneumoniae and Acinetobacter baumannii, into a first-in-human Phase 1 trial. Portuguese investor … more ➔
startupsBioInnovation Institute backs six startups with €8MCopenhagen’s BioInnovation Institute (BII) is providing six early-stage companies with €1.3 million each in convertible loans, taking its total financing of each startup to €1.8 million. more ➔
clinical dataNovartis’ Lp(a) drug misses Phase 3 endpointNovartis’ pelacarsen failed to reduce cardiovascular events in the first Phase 3 outcomes trial of an Lp(a)-lowering drug, despite successfully lowering the genetically driven cardiovascular risk … more ➔
drug deliveryNovartis commits $3.2B to subcutaneous deliveryNovartis could pay up to $3.223 billion (€2.8 billion) for access to Alteogen’s technology for turning intravenous biologics into subcutaneous drugs. Behind the eye-catching figure is more than patient … more ➔
anti-obesityMenarini pays up to €726M for Chinese obesity drugItalian pharma Menarini Group has licensed European rights to bofanglutide for obesity and excess weight, a long-acting GLP-1 receptor agonist from China’s Gan & Lee Pharmaceuticals dosed once every … more ➔
clinical dataTransgene cancer vaccine keeps patients relapse-free for three yearsFrench biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a randomized Phase 1 trial remained disease-free after three years, while three … more ➔
licensingGSK bets $1.3B on KRAS-EGFR conjugate from HUTCHMEDGSK has licensed ex-China rights to HUTCHMED’s HMPL-A830, an experimental antibody conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors, in a deal worth up to $1.295 billion (€1.12 … more ➔
FinancingNovaGo raises $30M to advance regenerative spinal cord therapySwiss biotech NovaGo Therapeutics has raised CHF 24 million ($30 million/€25.5 million) in a Series B round to advance its lead anti-Nogo-A antibody into a randomized proof-of-concept study in patients … more ➔
